Monoclonal antibody K312-based depletion of pluripotent cells from differentiated stem cell progeny prevents teratoma formation |
Park, Jongjin
(Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB))
Lee, Dong Gwang (Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Lee, Na Geum (Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Kwon, Min-Gi (Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Son, Yeon Sung (Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Son, Mi-Young (Stem Cell Convergence Research Center, KRIBB) Bae, Kwang-Hee (Metabolic Regulation Research Center, KRIBB) Lee, Jangwook (Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Park, Jong-Gil (Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Lee, Nam-Kyung (Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Min, Jeong-Ki (Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)) |
1 | Son YS, Seong RH, Ryu CJ et al (2011) Brief report: L1 cell adhesion molecule, a novel surface molecule of human embryonic stem cells, is essential for self-renewal and pluripotency. Stem Cells 29, 2094-2099 DOI |
2 | Park J, Son Y, Lee NG et al (2018) DSG2 is a functional cell surface marker for identification and isolation of human pluripotent stem cells. Stem Cell Rep 11, 115-127 DOI |
3 | Wesselschmidt RL (2011) The teratoma assay: an in vivo assessment of pluripotency. Methods Mol Biol 767, 231-241 DOI |
4 | Narsinh KH, Sun N, Sanchez-Freire V et al (2011) Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. J Clin Invest 121, 1217-1221 DOI |
5 | Lanctot PM, Gage FH and Varki AP (2007) The glycans of stem cells. Curr Opin Chem Biol 11, 373-380 DOI |
6 | Schopperle WM and DeWolf WC (2007) The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinoma. Stem Cells 25, 723-730 DOI |
7 | Park J, Lee NG, Oh M et al (2020) Selective elimination of human pluripotent stem cells by anti-Dsg2 antibody-doxorubicin conjugates. Biomaterials 259, 120265 DOI |
8 | Tang C, Lee AS, Volkmer JP et al (2011) An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol 29, 829-834 DOI |
9 | Ben-David U, Nudel N and Benvenisty N (2013) Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells. Nat Commun 4, 1992 DOI |
10 | Satomaa T, Heiskanen A, Mikkola M et al (2009) The N-glycome of human embryonic stem cells. BMC Cell Biol 10, 42 DOI |
11 | Brimble SN, Sherrer ES, Uhl EW et al (2007) The cell surface glycosphingolipids SSEA-3 and SSEA-4 are not essential for human ESC pluripotency. Stem Cells 25, 54-62 DOI |
12 | Trounson A and DeWitt ND (2016) Pluripotent stem cells progressing to the clinic. Nat Rev Mol Cell Biol 17, 194-200 DOI |
13 | Park J, Lee Y and Shin J et al (2019) Mitochondrial genome mutations in mesenchymal stem cell derived from human dental induced pluripotent stem cells. BMB Rep 52, 689-694 DOI |
14 | Choi HS, Kim WT and Ryu CJ (2014) Antibody approaches to prepare clinically transplantable cells from human embryonic stem cells: identification of human embryonic stem cell surface markers by monoclonal antibodies. Biotechnol J 9, 915-920 DOI |
15 | Wuputra K, Ku CC, Wu DC, Lin YC, Saito S and Yokoyama KK (2020) Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells. J Exp Clin Cancer Res 39, 100 DOI |
16 | Graf T and Stadtfeld M (2008) Heterogeneity of embryonic and adult stem cells. Cell Stem Cell 3, 480-483 DOI |
17 | Yamanaka S (2020) Pluripotent stem cell-based cell therapy-promise and challenges. Cell Stem Cell 27, 523-531 DOI |
18 | Blum B and Benvenisty N (2008) The tumorigenicity of human embryonic stem cells. Adv Cancer Res 100, 133-158 DOI |
19 | Ben-David U and Benvenisty N (2011) The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 11, 268-277 DOI |
20 | Nussbaum J, Minami E, Laflamme MA et al (2007) Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J 21, 1345-1357 DOI |